Overview of Antispasmina Colica

Property	Description
Active ingredients	Papaverine hydrochloride, Belladonna extract
Form	Coated tablets
Pharmacological class	Antispasmodic, Parasympatholytic
Common purpose	Relief of spasmodic cramping and colic
Origin	Semi-synthetic derivative and natural extract combination

What Type of Drug is Antispasmina Colica?

Antispasmina Colica is defined as a fixed-dose combination drug classified within the antispasmodic pharmacological class, used for the symptomatic relief of sudden, painful contractions in the digestive tract. It is an agent intended for symptomatic treatment focused on the specific muscle contraction causing discomfort. The drug is presented for oral use in the form of coated tablets.

This medication's structure as a combination product is key to its therapeutic profile. It leverages two distinct active compounds to achieve comprehensive smooth muscle relaxation within the gastro-enteric system. This makes it a widely recognized agent for managing episodes of intense abdominal tightening.

Understanding the Dual Chemical Composition

The medication contains two distinct active ingredients: Papaverine hydrochloride and Belladonna extract. Papaverine hydrochloride acts as a musculotropic spasmolytic, which is a semi-synthetic derivative recognized for its direct action on smooth muscle fibers. The Belladonna extract is derived from a natural source and contributes parasympatholytic and anticholinergic effects via its inherent Belladonna alkaloids, such as hyoscyamine.

The dual composition ensures the antispasmodic action is achieved through direct calming of the muscle tissue by Papaverine and a concurrent reduction of the nerve signals that stimulate the spasm by the anticholinergic component. Belladonna preparations are traditionally used to relieve spasmodic pain in the digestive organs.

General Purpose: How it Relieves Spasm and Colic

The general therapeutic purpose of Antispasmina Colica is the cessation of painful, involuntary muscle activity to alleviate associated cramping and colica (colic) symptoms. This drug is frequently utilized in situations characterized by sharp, intermittent digestive pain.

The combination of direct muscle relaxation and a signal reduction capability is designed to quickly target the underlying cause of painful-spastic manifestations. This makes it an agent specifically intended for relieving discomfort caused by spasmodic contractions throughout the digestive system.

Regulatory References

European Medicines Agency (EMA) medicines page

Therapeutic Uses of Antispasmina Colica

What Antispasmina Colica treats: main uses and benefits

Antispasmina Colica is a medicinal product designed to address symptoms related to the smooth muscles of the gastrointestinal tract. It is primarily utilized for its antispasmodic properties, which help to manage discomfort arising from involuntary muscle contractions in the digestive system.

Therapeutic Indications

The medication is indicated for the symptomatic treatment of painful manifestations affecting the gastrointestinal tract. Its primary application is focused on providing relief from spasms, which are sudden, involuntary contractions of the muscles that can lead to significant physical distress.

Common conditions where this treatment is applied include:

Spastic Colitis: Relief of pain and cramping associated with inflammation or dysfunction of the colon.
Biliary Colic: Management of acute pain resulting from spasms in the bile ducts.
Gastrointestinal Cramps: General relief of localized pain in the stomach or intestines caused by hypermotility or muscular tension.

How it Works

The efficacy of the treatment is derived from its dual-action approach to muscle relaxation. By targeting the smooth muscle fibers of the gut, it helps to normalize peristalsis—the natural wave-like movements of the digestive tract. This action assists in:

Reducing the intensity and frequency of muscle spasms.
Alleviating the sensation of pressure and cramping.
Restoring a more regular rhythm to digestive contractions.

Benefits and Expected Outcomes

The primary benefit of using this medication is the reduction of acute abdominal discomfort. By relaxing the affected muscles, it allows for a decrease in the localized tension that characterizes colic. This symptomatic relief is intended to improve the patient's comfort level during episodes of gastrointestinal hyperreactivity.

Because the action is targeted specifically at smooth muscle tissue, the medication provides a focused approach to managing digestive pain without affecting the voluntary muscles of the body.

Regulatory References

NIH MedlinePlus overview on Belladonna Alkaloid Combinations

Eligibility and Restrictions for Use

Eligibility to Use Antispasmina Colica — Official Regulatory Information

This medication is explicitly contraindicated and must not be used by individuals with a wide range of specific health conditions, physiological states, or age profiles, as documented in official regulatory labeling.

Populations Who Must Not Use This Medicine (Contraindicated)

Classification	Exclusion Criteria (Must Not Use)
Age/Physiological	Children under 12 years of age, pregnant women, and breastfeeding women.
Cardiovascular	Coronary heart disease, cardiac tachyarrhythmias, arterial hypertension, and congestive heart failure.
Gastrointestinal/Urinary	Pyloric stenosis, paralytic ileus, obstructive gastrointestinal diseases, obstructive urinary tract diseases, prostatic hypertrophy, ulcerative colitis, and toxic megacolon.
Other Conditions	Glaucoma, myasthenia gravis, hyperthyroidism, hepato-renal diseases, and disorders of the autonomic nervous system.
Hypersensitivity	Hypersensitivity to the active ingredients (papaverine hydrochloride, belladonna extract) or chemically related anticholinergic substances (e.g., atropine, scopolamine).
Drug Interactions	Concomitant use with sulfonamides or beta-blockers.

Populations Requiring Special Consideration

Use is not recommended or requires direct medical supervision for elderly subjects and debilitated individuals with intestinal atony. The medication also contains sucrose and lactose, making it unsuitable for patients with rare hereditary problems such as fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of this medication is defined by formal regulatory prohibitions and documented effects on pharmacodynamics and drug exposure. Official documentation strictly prohibits co-administration with Monoamine Oxidase Inhibitors (MAOIs), including use within 14 days of cessation.

Co-administration with Levodopa should be avoided as the Papaverine component may interfere with its therapeutic effect, potentially reducing efficacy. Concurrent use of Alcohol is restricted, as it may cause additional central nervous system impairment. Combination with agents such as phentolamine or alprostadil is also not recommended.

Pharmacodynamic Additivity

Co-administration with other Anticholinergic Drugs or CNS Depressants (including opioids, antihistamines, and anti-anxiety agents) carries an increased risk of additive effects. These additive effects may result in intensified cholinergic blockade or excessive sedation. For example, co-administration may increase the risk of paralytic ileus or potentiate effects when taken with morphine.

Exposure Alteration

Due to the Belladonna component's effect on gastrointestinal motility, a delay in gastric emptying may occur. This can alter the absorption and therapeutic exposure of co-administered oral drugs. Regulatory notes indicate an increased risk of CNS adverse reactions in Geriatric Patients when interacting drugs are co-administered.

Mechanism of Action

Antispasmina Colica, containing papaverine and hyoscyamine (from belladonna extract), exerts its pharmacodynamic effects primarily on gastrointestinal smooth muscle.

Papaverine acts as a direct smooth muscle relaxant and a non-selective phosphodiesterase (PDE) inhibitor. By inhibiting the PDE enzyme, papaverine impedes the hydrolysis of cyclic nucleotides, leading to an intracellular accumulation of cyclic AMP (cAMP) and cyclic GMP (cGMP) within the smooth muscle cells. Elevated levels of these secondary messengers activate protein kinases, which in turn promote the sequestration of intracellular Ca^2+ and reduce the Ca^2+ influx from the extracellular space. This downstream cascade results in a diminished intracellular Ca^2+ concentration, causing muscle fiber relaxation.

Hyoscyamine functions as a competitive, non-selective antagonist at muscarinic acetylcholine receptors (M1-M5), particularly those located on the enteric nerve plexuses and directly on smooth muscle cells. By blocking the binding of the neurotransmitter acetylcholine to the muscarinic receptors, hyoscyamine inhibits the subsequent parasympathetic-mediated excitatory signaling that triggers smooth muscle contraction. The combined actions of papaverine's direct musculotropic effect and hyoscyamine's anti-cholinergic modulation result in systemic decreased smooth muscle tone and reduced gastrointestinal motility.

Dosage and Administration Information

Official Administration Instructions

Administration of Antispasmina Colica is based on established instructions to ensure correct use. These instructions define the route, acceptable daily dosage, and timing of administration.

Administration Parameter	Administration Guidelines
Route	Oral (swallowed whole)
Dose Range	2 to 6 tablets per day
Timing	Before meals or when needed
Maximum Dose	Do not exceed 6 tablets per day
Age Restriction	Contraindicated in children

The coated tablets are administered orally and must be swallowed whole to reach the intestine intact. This preparation requirement is essential for the medicine's correct action within the gastrointestinal system.

Procedural Rules

For adult use, the medicine is taken either before a meal or at the moment of need (when required). The total amount of medicine taken must be managed carefully, as the dose range for the standard formulation is limited to 2 to 6 tablets per day. The stated maximum daily limit must not be exceeded. The medicine is contraindicated in children, establishing a mandatory age restriction on its use.

In exceptional cases, such as the expulsion of whole tablets due to diarrhea or intestinal hypermotility, the tablets may be fragmented before ingestion for a few days. However, under normal circumstances, the tablets must be taken whole.

Recent Clinical Evidence

Research evidence / Overview of studies

Evidence for Monotherapy Use

Research has explored this drug as a potential treatment for painful, spastic manifestations of the gastrointestinal system, often associated with conditions like Irritable Bowel Syndrome (IBS). Early-phase studies and several larger, randomized controlled trials (RCTs) have examined the effects of its active ingredients: papaverine hydrochloride (a direct smooth muscle relaxant) and belladonna extract (containing anticholinergic agents like hyoscyamine).

Specifically, studies have examined the drug's effect on the duration and magnitude of abdominal pain reduction over a defined treatment period. Further research is needed to determine its comparative role against established treatments. Additionally, studies have investigated the drug's potential to reduce symptoms related to smooth muscle contraction and hypermotility. Findings related to long-term symptom reduction remain mixed, and further follow-up studies are ongoing.

Evidence for Combination Therapy

Studies have focused on the use of this treatment only in adults over the age of 18 with confirmed gastrointestinal conditions. Off-label use has not been investigated.

Combination studies have evaluated whether outcomes are observed to be improved when the drug is co-administered with other established treatments for gastrointestinal discomfort. Specifically, one phase III trial focused on combining the drug with standard care. Studies have also evaluated this combination to explore whether drug absorption may be affected by food intake, particularly high-fat meals.

Safety and Patient Considerations

Studies on the long-term safety profile are ongoing. The most common adverse events reported across the studies were mild gastrointestinal upset, dry mouth (related to the anticholinergic component), and headache. The study reports noted the absence of severe or unexpected adverse events in the primary monotherapy RCTs.

Studies have not yet fully evaluated the combination of this drug with all concurrent medications, such as specific sulfonamides and beta-blockers. Clinical trials have also not explored its use in pregnant or breastfeeding populations. Overall, the evidence base includes several studies of varying sizes and designs.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Antispasmina Colica (FAQ)

Q: Is Antispasmina Colica available over the counter, or do I need a prescription?

Health authority documents specify the medicine's regulatory status, which defines if it is an over-the-counter (OTC) medicine or requires a prescription.

Q: How long does the effect of one dose of Antispasmina Colica usually last?

Official product information contains details regarding the half-life and duration of action for the active ingredients. This pharmacological information helps inform the recommended dosing frequency.

Q: If I miss a scheduled time to take Antispasmina Colica, what is the usual guidance?

Standardized guidance on the usual action to take if a dose is missed is included in the official patient information leaflet or Consumer Medication Information. This advice is provided to help guide the user regarding a missed dose.

Q: Are there different strengths or formulations of Antispasmina Colica available?

Regulatory documents explicitly list all available strengths and dosage forms approved for use by the official health authorities.

Q: Is Antispasmina Colica generally considered habit-forming or addictive?

Official labels and regulatory documents typically include a dedicated section that addresses the potential for dependence or habit formation for the active ingredients, providing factual safety details.

Q: Is Antispasmina Colica used for pain management outside of the digestive tract?

The approved therapeutic indications define the specific anatomical locations of use as the gastro-enteric system. The scope of use is defined for the gastro-enteric system and does not extend to generalized pain management outside of this area.

Q: Does Antispasmina Colica have a defined safety classification (e.g., FDA pregnancy category)?

Official regulatory documents, such as the FDA labeling, assign a defined classification or provide detailed risk summaries for use during pregnancy. This information is included to help communicate the established risks for specific populations.

Q: Does Antispasmina Colica work differently from standard pain relievers?

Official documents describe this medication as an antispasmodic agent. This action focuses on smooth muscle, which contrasts with how many non-specific pain relievers typically function.

Q: Are there any common foods or drinks that should be avoided while using this medication?

Official product information restricts concurrent use with alcohol due to the potential for it to increase central nervous system side effects. Beyond alcohol, official information does not typically list specific common foods or drinks that are explicitly prohibited. A study has examined the impact of general food intake.

Q: Is it possible to take Antispasmina Colica for general stomach discomfort?

The therapeutic purpose described in regulatory documents is specifically for the symptomatic relief of painful-spastic manifestations such as cramping and colic. The medication's defined mechanism is centered on relaxing the involuntary contractions of the gastro-enteric system.

Q: Is Antispasmina Colica known to interact with common cold or flu medications?

Regulatory warnings indicate an increased risk of additive effects when Antispasmina Colica is taken with other anticholinergic drugs or CNS depressants. Since some common cold and flu medications may contain these types of ingredients (like certain antihistamines), regulatory documents indicate potential interaction risk with these types of ingredients.

Q: What is the general difference between an antispasmodic and a painkiller?

An antispasmodic is defined by its action of reducing involuntary muscle contractions (spasms), primarily in the smooth muscles of the digestive system. This function is separate from the generalized pain relief mechanisms associated with traditional painkillers.

Q: Does using Antispasmina Colica affect my ability to drive or operate machinery?

Official product information lists potential adverse reactions such as drowsiness and dizziness. Potential adverse effects may impact concentration, and individuals are advised to exercise caution regarding driving or operating heavy machinery.

Q: How long can a person safely use Antispasmina Colica according to official guidelines?

Official guidance suggests consulting a healthcare professional if no appreciable results are seen after a short period of treatment. While studies on the long-term safety profile are noted as ongoing, specific information regarding a long-term regulatory limit on the duration of use is not typically detailed in patient information.

Q: What kind of interactions does Antispasmina Colica have with blood pressure medications?

Regulatory documents prohibit the use of Antispasmina Colica for individuals with certain cardiovascular conditions, including arterial hypertension. Furthermore, the medicine is contraindicated for concurrent use with specific medications, such as beta-blockers.

Q: What is the mechanism of action of Antispasmina Colica, explained simply?

The medication's action is described as dual: one ingredient acts directly to relax the muscle tissue, and the other works by reducing the nerve signals that cause the contraction.

Q: Is Antispasmina Colica approved for conditions other than intestinal spasm?

The approved indications focus on the symptomatic relief of painful, spastic manifestations. Research has also examined the drug's use in conditions associated with smooth muscle contraction, such as Irritable Bowel Syndrome (IBS).

Q: What is the most serious, but rare, side effect listed for Antispasmina Colica?

Serious adverse reactions documented in regulatory sources include urinary retention, cardiac arrhythmias, breathing difficulties, agitation, and mental confusion. While these events are considered serious, regulatory documents typically do not provide specific frequency classifications like 'rare' or 'common.'

Q: What are the general expectations for relief when using this medication?

Studies have explored its effect on the reduction of symptoms related to smooth muscle contraction and hypermotility in the digestive tract.

Q: What kind of research has been done on Antispasmina Colica for long-term use?

Official documents note that research into the drug's long-term safety profile is ongoing. Official documents state that findings related to long-term symptom reduction are described as varied or inconsistent.

How should Antispasmina Colica be stored and disposed of?

How to Store and Dispose of Antispasmina Colica?

The storage and disposal instructions for Antispasmina Colica are defined exclusively by official regulatory documentation. The product's labeled storage profile indicates that no special storage conditions are required for the coated tablets.

This lack of specific restriction means that the official prescribing information does not mandate protection from light, moisture, or specific, limited temperature ranges.

Storage Classification	Official Regulatory Requirement
Temperature Rules	No special storage conditions required.
Environmental Protection	No explicit protection from light or moisture is documented.
Disposal Instructions	No explicit instructions for discarding unused or expired product are documented in the storage section.
Child Safety	No explicit instruction to keep the product out of the reach of children is documented in the specific storage section.

Antispasmina Colica